Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its target price decreased by Bank of America from $23.00 to ...

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) have been assigned an average rating of ...

stock in favor of a historically cheap drugmaker that's more than doubled in less than two years. TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and ...

BofA lowered the firm’s price target on Teva (TEVA) to $20 from $23 and keeps a Buy rating on the shares. The firm revised lower its FY26 and ...

Teva Pharmaceutical Industries Ltd. continues to strengthen its global market position through strategic access initiatives ...

If you are looking for an AI stock that is more promising than TEVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI ...

Teva stock dropped 1%. The settlement, which resolves all outstanding patent litigation relating to Auvelity, will be submitted for review by the U.S. Federal Trade Commission and Department of ...

The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...

Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...